BioCentury | May 9, 2016
Clinical News

Micellular paclitaxel: Additional Phase III data

...III trial in 789 patients with epithelial ovarian cancer showed that 250 mg/m 2 IV Paclical...
...with recurrent epithelial cancer, primary peritoneal cancer and fallopian tube cancer. Oasmia previously reported that Paclical...
...NASDAQ:OASM), Uppsala, Sweden Pharmasyntez , Irkutsk, Russia Product: Micellular paclitaxel ( Apealea , Paclical )) ( OAS-PAC-100...
BioCentury | Feb 15, 2016
Clinical News

Micellular paclitaxel regulatory update

...MAA to EMA for Apealea/Paclical micellular paclitaxel to treat epithelial ovarian cancer in combination with carboplatin. Paclical...
...Oasmia Pharmaceutical AB (SSE:OASM; NASDAQ:OASM), Uppsala, Sweden Product: Micellular paclitaxel ( Apealea , Paclical ) ( OAS-PAC-100...
BioCentury | May 4, 2015
Clinical News

Micellular paclitaxel regulatory update

...Russia approved Paclical micellular paclitaxel from Oasmia to treat epithelial ovarian cancer in combination with carboplatin. Oasmia...
...11, 2013). Oasmia Pharmaceutical AB (SSE:OASM A), Uppsala, Sweden Product: Micellular paclitaxel ( Paclical ) ( OAS-PAC-100...
BioCentury | Jul 21, 2014
Clinical News

Paclical micellular paclitaxel: Phase III data

...Phase III trial in 789 patients with epithelial ovarian cancer showed that 250 mg/m 2 Paclical...
...OS data, the company said it will also submit an NDA to FDA for Paclical. Paclical...
...EU for the indication. Oasmia Pharmaceutical AB (SSE:OASM A), Uppsala, Sweden Product: Paclical micellular paclitaxel ( OAS-PAC-100...
BioCentury | Feb 11, 2013
Company News

Oasmia, Pharmasyntez sales and marketing update

...Oasmia granted Pharmasyntez exclusive commercialization and distribution rights to Paclical micellular paclitaxel in the Commonwealth of Independent...
...the water-soluble formulation of paclitaxel, with an approval to allow commercialization in the CIS region. Paclical...
BioCentury | Oct 20, 2012
Financial News

Oasmia raises $18.3M in rights issue

...15%) to SEK5.50. Oasmia is developing products for human and animal cancers. The company's Paclical micellular paclitaxel...
BioCentury | Oct 10, 2011
Clinical News

Paclical micellular paclitaxel: Completed Phase III enrollment

...enrollment of 650 patients in an open-label, European Phase III trial comparing 250 mg/m 2 Paclical...
...or fallopian tube cancer. In August, Oasmia reported interim data from 400 patients showing that Paclical...
...U.S. for the indication. Oasmia Pharmaceutical AB (SSE:OASM A), Uppsala, Sweden Product: Paclical micellular paclitaxel ( OAS-PAC-100...
BioCentury | Sep 12, 2011
Company News

Oasmia, Orion deal

...that it and Orion terminated a 2007 deal granting Orion distribution rights to Oasmia's Paclical micellular paclitaxel...
BioCentury | Aug 8, 2011
Finance

Highlights of weekly biotech stock moves

...week after reporting interim data from an open-label, European Phase III trial showing that Paclical micellular paclitaxel...
...the results, Oasmia said it will start the process of submitting EU regulatory applications for Paclical...
BioCentury | Aug 8, 2011
Clinical News

Paclical micellular paclitaxel: Interim Phase III data

...400 patients in an ongoing, open-label, European Phase III trial showed that 250 mg/m 2 Paclical...
...the results, Oasmia said it will immediately start the process of submitting regulatory applications for Paclical...
...U.S. for the indication. Oasmia Pharmaceutical AB (SSE:OASM A), Uppsala, Sweden Product: Paclical micellular paclitaxel ( OAS-PAC-100...
Items per page:
1 - 10 of 13